May 11 (Reuters) – Danish vaccine maker Bavarian Nordic on Monday raised its full-year revenue and earnings guidance after being awarded an additional option by the U.S. government under an existing contract for its smallpox vaccine.
The company raised its revenue guidance for 2026 to 5.5 billion to 5.7 billion Danish crowns ($866.93 million-$898.46 million), from its earlier outlook of 5 billion Danish crowns to 5.2 billion Danish crowns.
It also raised its earnings before interest, taxes, depreciation and amortisation (EBITDA) margin forecast for the full year to about 28%, from the 25% it had forecast in March.
The Copenhagen-listed company also said it received an additional contract option valued at $97 million from the U.S. Department of Health and Human Services to supply a freeze-dried formulation of its Jynneos smallpox vaccine.
The U.S. Food and Drug Administration approved Bavarian Nordic’s freeze-dried formulation of its mpox and smallpox vaccine in March.
Freeze drying is a method used to remove water from a product, to extend its shelf life and stability.
The pharmaceutical company had said it was contracted by the U.S. Biomedical Advanced Research and Development Authority to develop and supply the freeze-dried version of Jynneos for stockpiling.
($1 = 6.3442 Danish crowns)
(Reporting by Chandni Shah in Bengaluru; Editing by Shinjini Ganguli and Diti Pujara)
Comments